Improved survival in MDS patients receiving iron chelation therapy - a matched pair analysis of 188 patients from the Düsseldorf MDS registry

Leukemia Research
Judith NeukirchenNorbert Gattermann

Abstract

MDS patients are prone to develop transfusional iron overload. Iron overload may partly explain why transfusion dependency is associated with a decreased likelihood of survival. Our matched-pair analysis included 94 patients on long-term chelation therapy and 94 matched patients without it. All patients had iron overload, defined as serum ferritin (SF) above 1000 ng/ml or a history of multiple transfusions and SF ≥ 500 ng/ml. Median SF was 1954 ng/ml in chelated and 875 ng/ml in non-chelated patients. The difference in median survival (74 vs. 49 months, respectively; p=0.002) supports the idea that iron chelation therapy is beneficial for MDS patients.

References

Sep 28, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Aug 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Luca MalcovatiMario Cazzola
Mar 30, 2010·Leukemia Research·Heather A Leitch

❮ Previous
Next ❯

Citations

Oct 13, 2010·Annals of Hematology·Norbert Gattermann, Eliezer A Rachmilewitz
Feb 11, 2014·Best Practice & Research. Clinical Haematology·David P Steensma, Norbert Gattermann
Jul 30, 2014·Hematology/oncology Clinics of North America·Sylvia S Bottomley, Mark D Fleming
Sep 6, 2014·Best Practice & Research. Clinical Haematology·Gunnar Birgegård
Sep 4, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P FenauxUNKNOWN ESMO Guidelines Working Group
Jun 14, 2014·International Journal of Hematology·Bor-Sheng KoHwei-Fang Tien
Mar 25, 2014·European Journal of Pediatrics·Jelena RasconTadas Zvirblis
Mar 17, 2016·South Asian Journal of Cancer·Sachi Jain Taran, Rakesh Taran
Feb 18, 2014·Critical Reviews in Oncology/hematology·Sally TemrazAli Taher
Apr 5, 2016·Pharmacogenomics·Jessica CusatoAntonio D'Avolio
Aug 15, 2015·Journal of Comparative Effectiveness Research·Amer M ZeidanAmy J Davidoff
Mar 25, 2014·Lancet·Lionel AdèsPierre Fenaux
Apr 12, 2013·Blood·Pierre Fenaux, Lionel Adès
Aug 25, 2012·Blood·A Victor HoffbrandMaria Domenica Cappellini
Mar 10, 2017·Expert Review of Hematology·Maximilian Stahl, Amer M Zeidan
Oct 27, 2017·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·J C ShenM F Zhao
Nov 4, 2017·Pharmacogenetics and Genomics·Sarah AllegraAntonio D'Avolio
Nov 28, 2017·International Journal of Hematology·Norbert Gattermann
Sep 26, 2012·Tidsskrift for den Norske lægeforening : tidsskrift for praktisk medicin, ny række·Sigbjørn Berentsen
Jan 16, 2016·American Journal of Hematology·Naseema GangatAyalew Tefferi
Dec 10, 2017·Hematology·Aristoteles Giagounidis
Sep 3, 2013·Expert Review of Hematology·Mhairi MitchellAmer M Zeidan
Mar 24, 2020·Annals of Internal Medicine·Emanuele AngelucciUNKNOWN TELESTO Study Investigators
Apr 4, 2013·Expert Review of Hematology·Mehmet A ÖzcanZafer Gülbas
Mar 20, 2014·Expert Review of Anticancer Therapy·Drorit G Merkel, Arnon Nagler
Mar 19, 2014·European Journal of Haematology·Hiroshi OkabeKeiya Ozawa
Dec 6, 2017·Clinical and Experimental Pharmacology & Physiology·Sarah AllegraAntonio Piga

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.